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Results: A significant increase (P < 0.05) in feed consumption, body 
weight gain, relative weights of testis and epididymis and intratesticu-
lar cholesterol level, follicle stimulating hormone (FSH), luteinizing 
hormone (LH), and prolactin was found in rats received dimethoate. 
On the other side, a significant decrease (P < 0.05) in absolute weight 
of testes and epididymis, serum cholesterol and testosterone levels, 
serum acetylcholine esterase (AChE) activity ,total sperm count, 
motility and fertility index was observed compared with the control 
group. Histopathologic results also indicated enlargement of inter-
stitial space, inhibition of spermatogenesis, and variable degrees of 
degenerative changes in the seminiferous tubules up to total cellular 
destruction.
Conclusion: Our results proved that dimethoate, could act as neu-
roendocrine disruptor via inhibition of AChE activity and increase 
of acetylcholine level in brain. This effect might be linked to the 
suppression of the brain’s release of hormones that stimulate the 
gonadotrophic hormones (LH and FSH). So we have to be aware 
that dimethoate has detrimental effects on the male rat reproductive 
system.
Disclosure of Interest: None declared.
PP238—SyNTheSiS of The fiVe BaNgladeShi 
uNaNi mediCiNeS deriVaTiVeS: iN ViTro 
STudieS of Their PharmaCologiCal 
aCTiViTieS
M.A.H. Mollik*
Biological Sciences, Peoples Integrated Alliance, Bogra, 
Bangladesh
Introduction: The art of herbal healing has very deep roots in 
Bangladeshi culture and folklore. Unani medicines serve as a major 
source of primary health care for Bangladeshi people. The reasons for 
their use range from easy access, affordability, beliefs in traditional 
systems, and long-term safety. Unani medicines have been used to 
treat individuals infected with human immunodeficiency virus (HIV) 
and therefore need scientific validation, a view supported by the herb-
alists.
Patients (or Materials) and Methods: The studies aimed to evaluates 
the in vitro cytotoxicity, immune-modulatory, and anti-HIV activi-
ties of traditional multiple herbal preparations from the herbalists. 
Triphola, Mohasudarshan, Doshomula, Sarasvati, and Hingoshtak 
medicines were supplied by the herbalists.
Results: Changes in adenosine triphosphate and glutathione over 36 
hours were measured using luminometry. Changes in 13 cytokines 
were assayed using an enzyme-linked immunosorbent assay–based 
absorbance assay. Protective effects against HIV killing of metal-
lothionein-IV cells were tested using the cell proliferation kit assay, 
and antiviral activities was measured using an HIV-1 viral load 
assay. Cyclosporine and azidothymidine were used as positive con-
trols. Mohasudarshan, Doshomula, and Sarasvati induced a dose-
dependent toxicity on treated peripheral blood mononuclear cells by 
reducing adenosine triphosphate, and glutathione at high doses (P < 
0.001). These remedial preparations, along with Triphola, showed 
immunomodulatory activities by significantly (P < 0.001) chang-
ing the secretion of pro-inflammatory cytokines. Hingoshtak stimu-
lated the levels of adenosine triphosphate, and glutathione in treated 
peripheral blood mononuclear cells at all doses however this remedial 
did not show any immunomodulatory activities on cytokine secretion 
when compared with control cells. Doshomula, Mohasudarshan, and 
Triphola showed promising anti-HIV activities relative to azidothy-
midine (P < 0.01).
Conclusion: The studies have exposed that some of these traditional 
remedial preparations have at least 1 or all the properties of immu-
nostimulation, immunomodulation otherwise antiretroviral effects. 
Proper scientific studies conducted on these preparations may lead to 
discovery of more effective drugs than in use at present.
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Introduction: Leptospirosis has emerged as a globally spread infec-
tious disease that is caused by spirochete bacteria of the genus 
Leptospira. Xanthones from pericarp of Garcinia mangostana and 
their analogs widely used as medicinal agents against several infec-
tious diseases were examined for inhibitory activity and investigated 
for synergistic effects with antibiotics against Leptospira spp.
Patients (or Materials) and Methods: The minimal inhibitory con-
centrations (MIC) of 5 purified xanthones and 8 xanthone analogs 
were determined against 1 nonpathogenic L biflexa serovar Patoc 
and four pathogenic L. interrogans serovars Bataviae, Autumnalis, 
Javanica, and Saigon by using broth microdilution test. The synergis-
tic effects with penicillin G or ampicillin were evaluated by calculat-
ing the fractional inhibitory concentration (FIC) index.
Results: The 2 xanthones from mangosteen, γ -mangostin and garci-
none C, and the 2 xanthone analogs, 1,3,8-trihydroxyxanthone and 
1,3-dihydroxythioxanthone, showed the highest antileptospiral activ-
ities with the MIC varying from 100 to ≥ 800 µg/mL. Combinations 
of γ -mangostin with penicillin G and 1,3,8-trihydroxyxanthone with 
ampicillin generated synergistic effects at the FIC index of 0.05 to 
0.75 and 0.51 to 0.75, respectively. However, antagonistic activity 
against L interrogans serovar Saigon was observed when combining 
γ -mangostin with penicillin G.
Conclusion: The results demonstrated that the xanthones from G 
magostana and hydroxyxanthone analog inhibited growth of lepto-
spires and there were synergistic effects between these xanthones and 
antibiotics, which could enhance the efficacy of both drugs for the 
treatment of leptospirosis.
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Introduction: Objective: To compare the pharmaceutical quality 
of 7 generic levodopa/benserazide combination products marketed 
in Germany with the original product (Madopar® / Prolopa®). 
Madopar® / Prolopa®is a combination of levodopa (L-Dopa), the 
precursor of dopamine (DA), and benserazide, a dopamine decarbox-
ylase inhibitor (DDCI). It is indicated in the treatmentof Parkinson’s 
disease, dopamine-responsive dystonia, and restless legs syndrome.
Patients (or Materials) and Methods: Madopar®/Prolopa®125 
tablets and capsules were used as reference materials. The generic 
products tested (all 100 mg/25 mg formulations) included 4 tablet 
formulations (ie, Levodopa/Benserazid beta [Betapharm], Levodopa/
Benserazid-CT [CT Arzneimittel], dopadura B [Mylan dura], and 
Levodopa/Benserazid ratiopharm [ratiopharm]) and 3 capsulated 
